Zevra Therapeutics Inc. (ZVRA) - Total Liabilities
Based on the latest financial reports, Zevra Therapeutics Inc. (ZVRA) has total liabilities worth $136.95 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Zevra Therapeutics Inc. (ZVRA) long-term investment share to see how much of total assets are deployed in long-term investments.
Zevra Therapeutics Inc. - Total Liabilities Trend (2012–2024)
This chart illustrates how Zevra Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Zevra Therapeutics Inc..
Zevra Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Zevra Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangzhou Amsky Technology Co Ltd
SHE:300521
|
China | CN¥124.81 Million |
|
COOR Service Management AB
ST:COOR
|
Sweden | Skr5.73 Billion |
|
Farmacias Benavides S.A.B. de C.V.
MX:BEVIDESB
|
Mexico | MX$5.49 Billion |
|
SAMT Co. Ltd
KQ:031330
|
Korea | ₩498.09 Billion |
|
Gruvaktiebolaget Viscaria
ST:VISC
|
Sweden | Skr1.16 Billion |
|
Shenzhen Haoningda Meters Co Ltd
SHE:002356
|
China | CN¥63.42 Million |
|
Hubei Sanxia New Building Materials Co Ltd
SHG:600293
|
China | CN¥1.90 Billion |
|
Brisa Bridgestone Sabanci Lastik Sanayi ve Ticaret AS
IS:BRISA
|
Turkey | TL27.51 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Zevra Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Zevra Therapeutics Inc.'s balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zevra Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zevra Therapeutics Inc. (2012–2024)
The table below shows the annual total liabilities of Zevra Therapeutics Inc. from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $138.46 Million | +25.35% |
| 2023-12-31 | $110.46 Million | +174.65% |
| 2022-12-31 | $40.22 Million | +590.71% |
| 2021-12-31 | $5.82 Million | -92.50% |
| 2020-12-31 | $77.62 Million | -8.64% |
| 2019-12-31 | $84.96 Million | -8.95% |
| 2018-12-31 | $93.31 Million | -15.15% |
| 2017-12-31 | $109.97 Million | +6.17% |
| 2016-12-31 | $103.58 Million | +57.32% |
| 2015-12-31 | $65.84 Million | +73.20% |
| 2014-12-31 | $38.02 Million | +42.40% |
| 2013-12-31 | $26.70 Million | +650.04% |
| 2012-12-31 | $3.56 Million | -- |
About Zevra Therapeutics Inc.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under P… Read more